AKERO THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 19.65 USD | -5.53% |
|
-0.05% | -15.85% |
| 10/05 | Akero Therapeutics' Q1 Net Loss Widens; Cash Expected to Fund Operations Into H2 2027 | MT |
| 30/04 | Akero Therapeutics Appoints Scott Gangloff as Chief Technology Officer | CI |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
End-of-day quotes
End-of-day quotes
Compared values
| Sector | Change | 5d. change | 1st Jan change | 1-year change | 5-years change | Capi. | ST | MT | LT | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| AKERO THERAPEUTICS, INC. | Bio Therapeutic Drugs | -5.53% | -0.05% | -15.85% | -56.91% | - | 1.36B |  | | |
Technical Rankings Surperformance
- Stock Market
- Equities
- AKRO Stock
- Charts Akero Therapeutics, Inc.
- Comparison Chart
